A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 5
- 主要终点
- Maximum tolerated dose defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
研究概览
简要总结
This phase I trial studies the side effects and best dose of veliparib when given together with floxuridine in treating patients with epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer that has spread to other places in the body. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as floxuridine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with floxuridine may kill more tumor cells.
详细描述
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose of the combination of ABT-888 (veliparib) and intraperitoneal (IP) floxuridine in adult patients with advanced ovarian, primary peritoneal or fallopian tube cancer.
SECONDARY OBJECTIVES:
I. To describe the adverse event profile associated with this treatment combination.
II. To assess for preliminary evidence of efficacy, such as tumor responses, of the treatment combination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed epithelial ovarian, primary peritoneal or fallopian tube malignancy that is metastatic and for which standard curative measures do not exist
- •Disease confined to the intraperitoneal and retroperitoneal cavity; Note: nodal disease below the diaphragm, implants adherent to the surface of the liver or intrahepatic lesions will not be exclusionary; patients remain eligible if all intrahepatic tumor is debulked or ablated by the time treatment is initiated
- •EXPANSION PHASE ONLY: Evaluable or measurable disease with the largest nodule measuring less than 5 cm in greatest dimension by radiographic imaging after debulking procedure
- •Candidate for and willingness to have a surgically placed intraperitoneal catheter and tissue acquisition at the time of port placement; note: if an intraperitoneal catheter is already in place, a tumor biopsy will still be required; a guided core-needle biopsy is sufficient in these cases
- •Able to swallow and absorb the medication
- •Obtained =< 7 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
- •Obtained =< 7 days prior to registration: Platelets (PLT) >= 100,000/mm^3
- •Obtained =< 7 days prior to registration: Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
- •Obtained =< 7 days prior to registration: Creatinine =< 1.5 x institutional ULN
- •Obtained =< 7 days prior to registration: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x institutional ULN
- •Obtained =< 7 days prior to registration: Hemoglobin (Hgb) > 9.0 mg/dl
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- •Ability to provide informed written consent
- •Life expectancy >= 12 weeks
- •Women of childbearing potential only: negative pregnancy test done =< 7 days prior to registration
排除标准
- •Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy; note: patients with recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube will be allowed, if the investigator believes the study treatment is a better alternative to initiation platinum-based chemotherapy, such as patients with a prior platinum allergy or low volume disease for whom platinum-based therapy is deferred until a later date
- •More than 4 prior chemotherapy regimens; note: repeat use of regimens count as 1 prior regimen; switching front-line therapy regimens (for example, from intraperitoneal to intravenous therapy) for reasons other than progression will count as 1 prior therapy; bevacizumab and other 'targeted' agents will count in the total number of prior regimens; vaccine therapies will not count in the total of prior therapies
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Any of the following prior therapies:
- •Chemotherapy =< 28 days prior to registration
- •Mitomycin C/nitrosoureas =< 42 days prior to registration
- •Immunotherapy =< 28 days prior to registration
- •Biologic therapy =< 28 days prior to registration
- •Radiation therapy =< 28 days prior to registration
- •Investigational therapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation) =< 28 days prior to registration
- •Prior poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy
- •Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment
- •Significant cardiovascular disease defined as congestive heart failure (New York Heart Association class III or IV cardiac disease), angina pectoris requiring nitrate therapy or recent myocardial infarction (=< 6 months prior to registration)
- •Metastatic disease outside the intraperitoneal cavity and retroperitoneum, intrahepatic lesions, or pleural effusions; significant ascites precluding catheter placement; exception: intrahepatic lesions removed or planning to be removed during the debulking procedure
- •Any of the following:
- •Nursing women
- •Pregnant women
- •Women of childbearing potential who are unwilling to employ adequate contraception (non-barrier method)
- •Immunocompromised patients (other than that related to the use of corticosteroids) with the exception of patients known to be human immunodeficiency virus (HIV) positive and have a cluster of differentiation 4 (CD4) count > 400 and do not require antiretroviral therapy
- •Receiving any other investigational agent that would be considered a treatment for the primary neoplasm
- •Other active malignancy =< 1 year prior to registration
- •EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix
- •NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer
研究组 & 干预措施
Treatment (veliparib and floxuridine)
Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
干预措施: Floxuridine (Drug)
Treatment (veliparib and floxuridine)
Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
Treatment (veliparib and floxuridine)
Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
干预措施: Pharmacological Study (Other)
Treatment (veliparib and floxuridine)
Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
干预措施: Veliparib (Drug)
结局指标
主要结局
Maximum tolerated dose defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
时间窗: 21 days
The number and severity of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion. This will provide an indication of the level of tolerance for this treatment combination in this patient group.
次要结局
- Time until treatment related grade 3+ toxicity(Up to 3 months)
- Response profile assessed using Response Evaluation Criteria in Solid Tumors(Up to 3 months)
- Time to progression(Up to 3 months)
- Incidence of adverse events(Up to 3 months)
- Incidence of hematologic toxicity(Up to 3 months)
- Incidence of toxicities assessed using CTCAE version 4.0(Up to 3 months)
- Incidence of non-hematologic toxicities evaluated via the CTC standard toxicity grading(Up to 3 months)
- Time until any treatment related toxicity(Up to 3 months)
- Time until hematologic nadirs (white blood cell, absolute neutrophil count [ANC], platelets)(Up to 3 months)
- Time to treatment failure(From registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 3 months)